4.6 Article

HuR Reduces Radiation-Induced DNA Damage by Enhancing Expression of ARID1A

Journal

CANCERS
Volume 11, Issue 12, Pages -

Publisher

MDPI
DOI: 10.3390/cancers11122014

Keywords

ARID1A; BAF250a; SWI; SNF; HuR; ELAVL1; post-transcriptional regulation; RNA-binding protein; TNBC; radiation

Categories

Funding

  1. Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health (NIH) [P20 GM103639]
  2. Presbyterian Health Foundation (PHF) Seed Grant
  3. Stephenson Cancer Center - NCI Cancer Center Support Grant [P30 CA225520]
  4. OUHSC Department of Radiation Oncology Research Development Funds
  5. National Institutes of Health [R01 CA167516, CA233201]
  6. MERIT Review Grant from the Department of Veterans Affairs [101 BX003420A1]
  7. National Institute on Aging Intramural Research Program, National Institutes of Health

Ask authors/readers for more resources

Tumor suppressor ARID1A, a subunit of the chromatin remodeling complex SWI/SNF, regulates cell cycle progression, interacts with the tumor suppressor TP53, and prevents genomic instability. In addition, ARID1A has been shown to foster resistance to cancer therapy. By promoting non-homologous end joining (NHEJ), ARID1A enhances DNA repair. Consequently, ARID1A has been proposed as a promising therapeutic target to sensitize cancer cells to chemotherapy and radiation. Here, we report that ARID1A is regulated by human antigen R (HuR), an RNA-binding protein that is highly expressed in a wide range of cancers and enables resistance to chemotherapy and radiation. Our results indicate that HuR binds ARID1A mRNA, thereby increasing its stability in breast cancer cells. We further find that ARID1A expression suppresses the accumulation of DNA double-strand breaks (DSBs) caused by radiation and can rescue the loss of radioresistance triggered by HuR inhibition, suggesting that ARID1A plays an important role in HuR-driven resistance to radiation. Taken together, our work shows that HuR and ARID1A form an important regulatory axis in radiation resistance that can be targeted to improve radiotherapy in breast cancer patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available